Cytogenetic as an Important Tool for Diagnosis and Prognosis for Patients with Hypocellular Primary Myelodysplastic Syndrome

Table 2

Correlation of karyotypes and the clinical features in patients with hypocellular primary MDS.

Patient’s variables	Number of patients/frequency (%)	Karyotypes (%)		value	Evolution from MDS to AML	value	Mortality	value
		Normal	Abnormal
Age				< 0,05		NS*		< 0,05
≤18 years (pediatric patients)	39 (37%)	12 (31%)	27 (69%)		39/9		39/12
>18 years (adult patients)	66 (63%)	35 (53%)	31 (47%)		66/10		66/36
Sex				NS*		NS*		NS*
Male	56 (53%)	20 (36%)	36 (64%)		56/11		56/26
Female	49 (47%)	27 (55%)	22 (45%)		49/8		49/22
MDS subtypes/% of bone marrow blasts				< 0,0002		< 0,0001		< 0,0005
Initial stage; RA/<5%	81 (77%)	47 (58%)	34 (42%)		81/2		81/27
Advantage stages; RAEB and RAEB-t ≥5%	24 (23%)	0	24 (100%)		24/17		24/21
IPSS				< 0,0001		< 0,0001		< 0,001
Low	0 (0%)	—	—		—		—
Int-1	78 (74%)	47 (60%)	31 (40%)		78/0		78/25
Int-2	17 (16%)	0 (0%)	17 (100%)		17/9		17/13
High	10 (10%)	0 (0%)	10 (100%)		10/10		10/10

*No significance.